Company / Depreciation & Amortization
RIGEL PHARMACEUTICALS INC Depreciation & Amortization History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Depreciation & Amortization
$2.4M
FY2025
5-year range
$998.0K / $2.4M
FY2021-FY2025
Trend
+8.4%
vs FY2024
Sector context
#97 of 163
Health Care
What the data says
At $2M, RIGEL PHARMACEUTICALS INC's depreciation & amortization ranks #67 of 163 in the Health Care sector. Depreciation & Amortization has increased for 3 consecutive years, from $998,000 in FY2022 to $2M in FY2025.
Based on SEC 10-K filings.
$2M in FY2025 with a 5-year CAGR of +27.9%.
Increased from $1M to $2M over the past 2 years.
Health Care sector context is included.
Depreciation & Amortization over time
Growth rates
- 3-Year CAGR
- +34.3%
- 5-Year CAGR
- +27.9%
- 10-Year CAGR
- -
Sector benchmark
#67 of 163 in Health CareTop 40% of 163This company $2.4M Sector average $219.4M
▼
-98.9% below sector average
Key checks
Key Insights
- RIGEL PHARMACEUTICALS INC's depreciation & amortization has grown for 3 consecutive years.
- 5-year CAGR of +27.9%, indicating consistent growth.
- In FY2025, depreciation & amortization increased 8.4% year-over-year.
- Ranks #97 out of 163 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 1.19 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Depreciation & AmortizationValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $2.4M | +8.4% |
| FY2024 | $2.2M | +80.0% |
| FY2023 | $1.2M | +24.0% |
| FY2022 | $998.0K | -14.1% |
| FY2021 | $1.2M | +64.6% |
| FY2020 | $706.0K | +3.4% |
| FY2019 | $683.0K | -27.4% |
| FY2018 | $941.0K | +102.4% |
| FY2017 | $465.0K | -50.6% |
| FY2016 | $941.0K | -34.6% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026